D
iabetes mellitus is a leading cause of death in the United States and is associated with microvascular and macrovascular complications. Approximately 29.1 million persons, or 9.3% of the U.S. population, have type 2 diabetes (1). In 2012, the total direct and indirect costs associated with diabetes in the United States were $245 billion (1) . Markedly elevated glucose levels can result in subacute symptoms, such as polyuria, polydipsia, weight loss, and dehydration. Over time, the metabolic derangements associated with diabetes may lead to vision loss, painful neuropathy or sensory loss, foot ulcers, amputations, myocardial infarctions, strokes, and end-stage renal disease. Lowering blood glucose may decrease risk for complications, but lowering strategies come with harms, patient burden, and costs.
Blood glucose can be measured in various ways, including the hemoglobin A 1c (HbA 1c ; also called glycosylated or glycated hemoglobin) level, which approximates average blood glucose control over about 3 months. As with all laboratory tests, HbA 1c measurements are associated with variability (2) and can vary further with race and ethnicity (3) (4) (5) . Guidelines have historically recommended initiation or intensification of 
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GUIDANCE STATEMENT FOCUS AND TARGET POPULATION
The purpose of this American College of Physicians (ACP) guidance statement is to critically review the available guidelines from various organizations and the evidence included therein to assist clinicians in making decisions about targets when using pharmacologic therapy in adults with type 2 diabetes. Recent data suggesting that newer agents reduce cardiovascular morbidity and mortality in high-risk patients with type 2 diabetes have prompted calls for a fundamental shift in diabetes management. Some anticipate that treatment decisions will eventually be based more on cardiovascular risk than achievement of specific HbA 1c targets, analogous to recent changes in lipid management. However, for the foreseeable future, glycemic targets will continue to influence management decisions by front-line clinicians (6) . This statement focuses on the benefits and harms of targeting lower versus higher HbA 1c levels and does not cover use of specific medications outside of their use to achieve HbA 1c targets. The intended audience is all clinicians, and the target population is nonpregnant adults with type 2 diabetes.
METHODS
The Clinical Guidelines Committee (CGC) of ACP develops guidance statements on topics where several conflicting guidelines are available. We provide clinicians with a rigorous review of the guidelines and the evidence they include. We then adopt the clinical recommendations if we agree with their evaluation of benefits and harms or adapt them if changes are needed based on our assessment of the recommendations and evidence.
Data Sources and Guideline Selection
We searched the National Guideline Clearinghouse and the Guidelines International Network library (May 2017) for guidelines on recommended HbA 1c targets in the treatment of type 2 diabetes in nonpregnant outpatient adults. We included guidelines that were developed by national organizations, were published in English, and targeted the correct population. We reviewed titles and abstracts and excluded guidelines that were modified or adapted from other organizations or addressed specific populations (such as pregnant women or patients with kidney disease). Our search yielded guidelines from the National Institute for Health and Care Excellence (NICE) (7) and the Institute for Clinical Systems Improvement (ICSI) (8) . On the basis of the knowledge and expertise of ACP CGC members, we also selected the following 4 guidelines not identified in either database at the time of the search but commonly used in clinical practice: the American Association of Clinical Endocrinologists and American College of Endocrinology (AACE/ACE) guideline (9), the American Diabetes Association (ADA) guideline (10), the Scottish Intercollegiate Guidelines Network (SIGN) guideline (11) , and the U.S. Department of Veterans Affairs and Department of Defense (VA/DoD) guideline (12) .
Quality Assessment
Six coauthors independently reviewed and assessed each guideline using the AGREE II (Appraisal of Guidelines for Research and Evaluation II) instrument (13) . This instrument asks 23 questions in the following 6 domains: scope and purpose, stakeholder involvement, rigor of development, clarity of presentation, applicability, and editorial independence. The authors scored each guideline independently, and the scores were compared (Appendix Figure and Appendix Table  1 , available at Annals.org). Authors then provided a summary determination of whether they "would recommend this guideline for use" by recording "yes," "no," or "yes with modifications."
Peer Review
The draft guidance statement was peer-reviewed through Annals of Internal Medicine and was posted online for comments from ACP Regents and Governors, who represent ACP members at the regional level. The final guidance statement incorporated comments from peer reviewers and ACP Regents and Governors.
Public Panel Review
The development of this guidance statement also included perspectives, values, and preferences of 2 CGC members who represent the public and a 7-member public panel.
SUMMARY OF EVALUATED GUIDELINES USING THE AGREE II INSTRUMENT
We reviewed and rated 6 guidelines (AACE/ACE [9] , ADA [10] , ICSI [8] , NICE [7] , SIGN [11] , and VA/DoD [12] ), focusing solely on sections addressing HbA 1c targets in patients with type 2 diabetes. Appendix Table 1 shows the detailed scaled domain scores and average quality ratings for each guideline, and the Appendix Figure shows average AGREE II scores for each item in each of the 6 domains. The fundamental difference between high-and low-scoring guidelines was methodology. The 2 lowest-scoring guidelines, AACE/ACE and ADA, scored lowest on stakeholder involvement, applicability, editorial independence, and scientific rigor. A systematic review is the backbone for any trustworthy guideline, but some guidelines might not be based on a systematic review or may not have made the review publicly available (14, 15) .
Several factors were important in considering guideline quality. For example, although many guidelines described benefits, adverse effects, and the strength and limitations of evidence or linked the evidence to the recommendation, they often inadequately described how they had considered or weighted these CLINICAL GUIDELINE ACP Guidance Statement on HbA 1c Targets With Pharmacologic Therapy factors in developing the final recommendations. The guidelines frequently relied on selective reporting of studies or outcomes and focused on relative versus absolute effects and asymptomatic surrogate measures rather than patient-centered health outcomes.
All of the reviewed guidelines recommend individualizing HbA 1c targets on the basis of patient characteristics, such as comorbid conditions and risk for hypoglycemia (Appendix, available at Annals.org). The ADA and SIGN guidelines recommend a target of 7% for the general population, whereas AACE/ACE recommends 6.5% (if it can be achieved safely). The NICE guideline specifies 6.5% or 7%, depending on the patient's treatment regimen. Both ICSI and VA/DoD recommend target ranges. The ICSI guideline recommends less than 7% to less than 8% based on patient factors, whereas the VA/DoD recommends the following target ranges based on life expectancy and comorbid conditions: 6% to 7% for patients with a life expectancy greater than 10 to 15 years and no or mild microvascular complications; 7% to 8.5% for those with established microvascular or macrovascular disease, comorbid conditions, or a life expectancy of 5 to 10 years; and 8% to 9% for those with a life expectancy less than 5 years, significant comorbid conditions, advanced complications of diabetes, or difficulties in self-management attributable to mental status, disability, or other factors (12) . All guidelines recognize that HbA 1c targets can be higher in patients with comorbid conditions and limited life expectancy.
We looked into the evidence presented in these guidelines, specifically 5 large, long-term randomized trials with a "treat-to-target" strategy and corresponding reports on extended follow-up (16 -23) . We summarize below the individual studies and resulting benefits and harms. Note that recent studies evaluating the effectiveness and safety of several newer diabetes drugs (for example, recently approved sodium-glucose cotransporter-2 inhibitors, dipeptidyl peptidase-4 inhibitors, and glucagon-like peptide-1 receptor agonists) were not considered in guideline sections pertaining to HbA 1c targets because these studies were not designed to evaluate treat-to-target strategies. Therefore, their findings are not described here.
BENEFITS AND HARMS OF LOWER HBA 1C TARGETS: EVIDENCE FROM CLINICAL TRIALS
Five large, long-term randomized controlled trials investigated intensive (achieved HbA 1c levels, 6.3% to 7.4%) versus less intensive (achieved HbA 1c levels, 7.3% to 8.4%) treatment target strategies in adults (average baseline age, 53 to 66 years). They found that the main effect of more intensive glycemic control is small absolute reductions in risk for microvascular surrogate events, such as retinopathy detected on ophthalmologic screening or nephropathy defined by development or progression of albuminuria (Appendix Table 2 , available at Annals.org) (16 -23 In all studies, patients randomly assigned to more intensive therapy required more antiglycemic medications at higher doses, which led to more adverse events than in the less intensive groups. In 1 study, very intensive control resulted in an increased risk for death (18) .
Appendix Table 2 . Intensive therapy did not reduce risk for microvascular outcomes (including renal failure, doubling of serum creatinine, visual impairment, retinal photocoagulation, and neuropathy) but led to small absolute reductions in the onset of albuminuria. Additional follow-up through a median of 5 years confirmed the original report's findings (achieved HbA 1c levels: intensive group, 7.2%; standard group, 7.6%) (19) .
The trial was stopped early because more intensive glycemic control was associated with a 22% increase in all-cause mortality, a 35% increase in cardiovascularrelated death, and a 3-fold increase in risk for severe hypoglycemia (18) . More intensive treatment also resulted in increased weight gain of more than 10 kg (27.8% vs. 14.1%) and increased fluid retention.
ADVANCE Trial
The ADVANCE trial enrolled participants with a mean baseline age of 66 years and mean baseline 
UKPDS Trials
The UKPDS trials involved 2 separate studies evaluating intensive glycemic control versus conventional therapy (diet and subsequent treatments if marked hyperglycemia persisted) in adults (mean age, 54 years) with newly diagnosed type 2 diabetes. One third of participants had retinopathy at baseline. The larger UKPDS 33 trial (23) (n = 3867; mean baseline age, 54 years) compared intensive glycemic control (target fasting plasma glucose level <6 mmol/L [108 mg/dL]; median attained HbA 1c level, 7%) using either sulfonylureas or insulin versus less stringent control (target fasting plasma glucose best achievable with diet; median attained HbA 1c level, 7.9%) using diet and added hypoglycemic agents if patients developed marked hyperglycemia. At a median follow-up of 10 years, intensive control reduced any diabetes-related end point by a relative 12% (CI, 1% to 21%) (P = 0.029). The absolute difference was 5.1 events per 1000 patient-years. This was largely due to a reduction in the composite outcome of microvascular end points, which comprised retinal photocoagulation for asymptomatic retinal findings detected on screening (relative risk reduction, 25% [CI, 7% to 40%]; P = 0.0099). The study found no differences in diabetes-related death (relative reduction, 10% [CI, Ϫ11% to 27%]; P = 0.34), all-cause mortality (relative reduction, 6% [CI, Ϫ10% to 20%]; P = 0.44), myocardial infarction, stroke, or amputation (23).
The UKPDS 34 trial (22) assessed intensive therapy with metformin (median attained HbA 1c level, 7.4%) versus conventional therapy (median attained HbA 1c level, 8.0%), primarily in overweight adults (n = 753). Supplementary and secondary analyses included participants from UKDPS 33 who subsequently received metformin for fasting plasma glucose levels that were persistently high. Compared with the conventional treatment group (receiving dietary advice or additional nonintensive pharmacologic therapy if they had marked hyperglycemia), patients initially allocated to metformin (n = 342) had relative risk reductions of 32% (CI, 13% to 47%) (P = 0.0023) for any diabetes-related end point, 42% (CI, 9% to 63%) (P = 0.017) for diabetes-related death, and 36% (CI, 9% to 55%) (P = 0.011) for all-cause mortality. This equates to absolute reductions in diabetes-related and all-cause mortality of approximately 5 and 7 deaths per 1000 patient-years, respectively. These reductions were greater than those attained with intensive therapy with sulfonylureas or insulin. However, early addition of metformin to sulfonylureas resulted in an increased risk for diabetesrelated death (P = 0.039) compared with continued treatment with sulfonylureas alone.
On extended follow-up (median time from randomization, 17 years), 3277 patients originally enrolled in UKPDS 33 or 34 who received intensive glucose control with sulfonylureas or insulin had a 9% relative reduction of borderline statistical significance in any diabetes-related end point (risk ratio, 0.91 [CI, 0.83 to 0.99]; P = 0.04) and an absolute reduction in all-cause mortality (3.5 deaths per 1000 patient-years; P = 0.007) (16) . In the metformin-intensive therapy group, risk reductions persisted for any diabetes-related end point (risk reduction, 21%; 8.2 events per 1000 patient-years; P = 0.01), myocardial infarction (risk reduction, 33%; 6.3 events per 1000 patient-years; P = 0.005), and allcause mortality (risk reduction, 27%; 7.2 deaths per 1000 patient-years; P = 0.002).
Hypoglycemic events were much more common in the intensive than standard treatment groups of the UKPDS trials (approximately 30% vs. 1% annually) (23). Early addition of metformin to sulfonylureas resulted in an increased risk for diabetes-related death (P = 0.039) compared with continued treatment with sulfonylureas alone.
VADT
The VADT compared patients (mean age, 60 years; median baseline HbA 1c level, 9.4%) in an intensive therapy group (median achieved HbA 1c level, 6.9%) with those in a standard therapy group (median achieved HbA 1c level, 8.4%). The trial targeted an absolute between-group difference in HbA 1c level of 1.5 percentage points and found no reduction in major cardiovascular events, death, or microvascular events, except for "any increase in albuminuria," over a median follow-up of 5.6 years (21). The intensive therapy group had fewer cardiovascular events over an extended follow-up of about 12 years (HR, 0.83 [CI, 0.70 to 0.99]; P = 0.04). However, the absolute effect was small (8.6 events per 1000 patient-years), and the outcome included hospitalization for new or worsening heart failure and asymptomatic ejection fractions of less than 40%. The investigators found no reduction in all-cause mortality (HR, 1.05 [CI, 0.89 to 1.25]) or cardiovascularrelated death (HR, 0.88 (CI, 0.64 to 1.20) (17) .
Severe and any hypoglycemia were more common in the intensive therapy group than the standard therapy group. This included a 3-fold higher rate of episodes with impaired consciousness (9 vs. 3 episodes per 100 patient-years). Serious adverse events were also more common in the intensive therapy group (24.1% vs. 17.6%; P = 0.05); dyspnea was the most common (P = 0.006) (21 All of the assessed guidelines recommend personalizing HbA 1c goals for individual patients (Appendix) (7-12). The benefits and harms of more versus less intensive glycemic control may be finely balanced for many persons and vary according to expected duration of treatment, comorbid conditions, risk factors for hypoglycemia, and choice of medication. The choice of glycemic target also depends on consideration of other variables, such as risk for hypoglycemia, weight gain, and other drug-related adverse effects, as well as the patient's age, life expectancy, other chronic conditions, functional and cognitive impairments, fall risk, ability to adhere to treatment, and medication burden and cost.
Guidance Statement 2: Clinicians should aim to achieve an HbA 1c level between 7% and 8% in most patients with type 2 diabetes.
Most of the guidelines referred to 5 trials as the rationale for their HbA 1c targets of 7% or 8% (Appendix Table 2 ) (19 -23). Collectively, these trials showed that treating to targets of 7% or less compared with targets around 8% did not reduce death or macrovascular events over about 5 to 10 years of treatment but did result in substantial harms, including but not limited to hypoglycemia. Our guidance statement is adapted from and is most consistent with the ICSI guideline, which recommends an HbA 1c target range between less than 7% and less than 8% (8) . The VA/DoD guideline also specifies ranges rather than specific targets and selects them according to life expectancy, comorbid conditions, and other factors (12) . Including ranges for recommended goals also allows for variability in individual HbA 1c measurements.
The ICSI guideline highlights that efforts to achieve HbA 1c levels below 7% may increase risk for death, weight gain, hypoglycemia, and other adverse effects in many patients (8) , and we share these concerns. Of the 3 trials achieving an HbA 1c level less than 7%, none showed a reduction in all-cause or cardiovascularrelated death (18, 20, 21) .
The guidelines recommending lower targets (below 7% or below 6.5%) give the rationale that more intensive glycemic control reduces microvascular events over many years of treatment. Of note, however, the evidence for reduction is inconsistent, and reductions were seen only in surrogate microvascular end points, such as progression of proteinuria or receipt of retinal photocoagulation. Trials did not show substantial reductions in clinical microvascular events. In addition, the ACCORD trial found an increased risk for death with an HbA 1c target of less than 6.5% (18) .
Most of the guidelines noted that a target in the lower end of the range (7%) applied best to patients with newly diagnosed diabetes and those without substantial diabetes-related complications. The rationale for this is based on results from the UKPDS. This trial showed that treatment to a target of about 7% with a sulfonylurea and insulin (if needed) in adults with newly diagnosed diabetes did not reduce risk for any diabetes-related end point or all-cause mortality after 10 years but was associated with a small absolute reduction in these outcomes after 17 years (16, 23) . A substudy (UKPDS 34) also showed a modest reduction in diabetes-related end points and all-cause mortality with metformin in overweight or obese adults (2, 12) .
All laboratory measurements, including HbA 1c levels, are associated with variability. Therefore, a clinician should consider the variability of HbA 1c test results when selecting goals or making therapeutic decisions.
Any benefit of more intensive glycemic control likely requires a long time to manifest. Thus, more stringent targets may be appropriate for patients who have a long life expectancy (>15 years) and are interested in more intensive glycemic control with pharmacologic therapy despite the risk for harms, including but not limited to hypoglycemia, patient burden, and pharmacologic costs.
Although this guidance statement focuses on pharmacologic glycemic control, a lower treatment target is appropriate if achievable with diet and lifestyle modifications. Clinicians should counsel patients and emphasize the importance of lifestyle interventions, including exercise, dietary changes, and weight loss, to achieve good glycemic control. Smoking cessation, adequate blood pressure control, and lipid management are also indicated in patients with type 2 diabetes and, for many patients, may take priority over achieving glycemic control, especially for preventing macrovascular complications.
Guidance Statement 3: Clinicians should consider deintensifying pharmacologic therapy in patients with type 2 diabetes who achieve HbA 1c levels less than 6.5%.
No trials show that targeting HbA 1c levels below 6.5% in diabetic patients improves clinical outcomes, and pharmacologic treatment to below this target has substantial harms. The ACCORD trial, which targeted an HbA 1c level less than 6.5% and achieved the lowest level of the included studies (6.4%), was discontinued early because of increased overall and cardiovascularrelated death and severe hypoglycemic events (18) . The ADVANCE study also failed to find a statistically significant clinical benefit and had more adverse effects with an achieved median HbA 1c level of 6.4% than with 7.0%. In addition, more intensive treatment to achieve a lower target is more costly and is associated with increased patient burden. Therefore, if a patient achieves an HbA 1c level less than 6.5%, the clinician should deintensify treatment by reducing the dosage, removing a medication if the patient is receiving more than 1, or discontinuing pharmacologic treatment.
Although other drugs have been associated with harms, the balance between benefits and harms is uncertain with metformin for lower HbA 1c levels. Metformin is not associated with hypoglycemia and is gen- All of the evaluated guidelines suggest relaxing HbA 1c targets for patients with multiple comorbid conditions, limited life expectancy, or increased risk for hypoglycemia (7-11). Setting stringent targets in these populations is not an optimal approach, and clinicians should instead focus on treating to reduce symptoms from both disease and treatment. The ACP guidance statement in persons with a life expectancy less than 10 years is based on the small death or cardiovascular benefit of lower HbA 1c targets through at least 10 years, which should be balanced with treatment harms, including but not limited to hypoglycemia and patient views of treatment burden. For example, a modeling study has examined how treatment burden affects the benefits of intensive versus moderate glycemic control in patients with type 2 diabetes (25) . Authors used microvascular benefits shown in UKDPS 33, as well as reductions in congenital heart disease events from observational studies and the long-term follow-up of UKPDS, to assess lifetime benefits of glycemic targets. Even with low estimates of treatment-related adverse effects and patient-perceived treatment burden, achieving more intensive target HbA 1c levels of 7.5% or below rather than 8.5% (especially if using insulin) resulted in net harm in most patients aged 55 years or older.
The Figure summarizes the guidance statements and clinical considerations.
MULTIPLE CHRONIC CONDITIONS: APPLICATION TO OLDER POPULATIONS
Consideration of how this evidence base applies in older populations is important because of the high proportion of older patients with multiple chronic comorbid conditions, the frequency of polypharmacy and potential for drug interactions, and the consequent likelihood that the balance of benefits and harms is different in older patients. For patients with multiple comorbid conditions, including renal failure, liver failure, end-stage disease complications, cognitive impairment, advanced microvascular or macrovascular complications, or any other conditions that limit life expectancy, the harms of more intensive HbA 1c targets outweigh the benefits. Many guidelines also discuss the role of less intensive targets for older adults. In these patients, the goal should be to minimize symptoms rather than achieve a specific HbA 1c target.
INSUFFICIENT AREAS OF EVIDENCE
Evidence from trials included here is insufficient to evaluate the effect of HbA 1c targets between 6.5% and 7% on clinical outcomes, and further research would be needed to close this gap.
HIGH-VALUE CARE
ACP believes that clinicians should reevaluate HbA 1c levels and revise treatment strategies on the basis of changes in the balance of benefits and harms due to changed costs of care and patient preferences, general health, and life expectancy. In persons who reach HbA 1c levels less than 6.5% with drug treatment, deescalation of therapy (by reducing dosage or number of drugs) is warranted to reduce harms, patient burden, and costs of treatment. Generic medications are preferred when available. ACP recently provided recommendations on pharmacologic treatment of type 2 diabetes (24).
POLICY IMPLICATION FOR PERFORMANCE MEASURES
ACP suggests that any physician performance measures developed to evaluate quality of care should not have a target HbA 1c level below 8% for any patient population and should not have any HbA 1c targets for older adults (for example, aged ≥80 years) or younger persons with limited life expectancy due to serious comorbid conditions. Note: Guidance statements are "guides" only and may not apply to all patients and all clinical situations. Thus, they are not intended to override clinicians' judgment. All ACP guidance statements are considered automatically withdrawn or invalid 5 years after publication, or once an update has been issued.
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Dr. Vijan was recused from voting on the recommendations for an active direct financial conflict. Dr. Manaker was recused from voting on the recommendations for an active indirect financial conflict. A record of disclosures of interest and management of conflicts of interest is kept for each CGC meeting and conference call and can be viewed at www.acponline.org /clinical_information/guidelines/guidelines/conflicts_cgc.htm. Glucose targets should be individualized and take into account life expectancy, disease duration, presence or absence of micro-and macrovascular complications, CVD [cardiovascular disease] risk factors, comorbid conditions, and risk for hypoglycemia, as well as the patient's psychological status (Grade A; BEL [best evidence level] 1). In general, the goal of therapy should be an A1C level ≤6.5% for most nonpregnant adults, if it can be achieved safely . . . (Grade D; BEL 4) . . . . In adults with recent onset of T2D [type 2 diabetes] and no clinically significant CVD, glycemic control aimed at normal (or near-normal) glycemia should be considered, with the aim of preventing the development of micro-and macrovascular complications over a lifetime, if it can be achieved without substantial hypoglycemia or other unacceptable adverse consequences (Grade A; BEL 1). . . . A less stringent glucose goal should be considered (A1C 7 to 8%) in patients with history of severe hypoglycemia, limited life expectancy, advanced renal disease or macrovascular complications, extensive comorbid conditions, or long-standing DM [diabetes mellitus] in which the A1C goal has been difficult to attain despite intensive efforts, so long as the patient remains free of polydipsia, polyuria, polyphagia, and other hyperglycemiaassociated symptoms (Grade A; BEL 1). (9) Comments According to the AACE/ACE grading scheme, "Grade A; BEL 1" indicates highest-quality evidence with little or no effect from subjective factors on recommendation (evidence mapped to recommendation) and "Grade D; BEL 4" indicates lowest-quality evidence with little or no effect from subjective factors on recommendation (9) .
Requests for Single
This guideline is a consensus, expert-based guideline, with no systematic review of evidence. In general, the methods behind the clinical recommendations were not clearly presented. This guideline recommends a very low target HbA 1c level in most adults (≤6.5%) if it can be achieved safely, although a higher target (7% to 8%) is recommended in patients with multiple chronic conditions or shorter lifespan. 
ADA

Comments
According to the ADA grading scheme, Grade A is "[c]lear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered." Grade B is "[s]upportive evidence from wellconducted cohort studies" (10) .
This guideline does not clearly present methods or details about the systematic reviews that were used to develop the recommendations. It states that HbA 1c targets should be less than 7% in most adults, even more stringent (<6.5%) in select cases treated with lifestyle or metformin alone, and less stringent (<8%) in patients with multiple chronic conditions.
ICSI
Recommendation
A clinician should personalize goals with patients diagnosed with T2DM [type 2 diabetes mellitus] to achieve glycemic control with a hemoglobin A1c < 7% to < 8% depending on individual patient factors [strong recommendation, high-quality evidence]. (8)
Comments
The ICSI clearly presents the evidence and methodology behind their clinical recommendations. It specifies that an HbA 1c target of less than 8% may be more appropriate than 7% in persons with cardiovascular disease or high cardiovascular risk, history of severe hypoglycemia requiring assistance, polypharmacy issues, limited life expectancy (<10 years), cognitive impairment, or extensive comorbid conditions (renal or liver failure or end-stage disease complications). It highlights that efforts to achieve HbA 1c levels below 7% may increase risk for death, weight gain, hypoglycemia, and other adverse effects in many patients.
NICE
Recommendations
Involve adults with type 2 diabetes in decisions about their individual HbA1c target. Encourage them to achieve the target and maintain it unless any resulting adverse effects (including hypoglycaemia), or their efforts to achieve their target, impair their quality of life. . . . For adults with type 2 diabetes managed either by lifestyle and diet, or by lifestyle and diet combined with a single drug not associated with hypoglycaemia, support the person to aim for an HbA1c level of 48 mmol/mol (6.5%). For adults on a drug associated with hypoglycaemia, support the person to aim for an HbA1c level of 53 mmol/mol (7.0%). . . . In adults with type 2 diabetes, if HbA1c levels are not adequately controlled by a single drug and rise to 58 mmol/mol (7.5%) or higher: Y reinforce advice about diet, lifestyle and adherence to drug treatment and Y support the person to aim for an HbA1c level of 53 mmol/mol (7.0%) and Y intensify drug treatment. . . . Consider relaxing the target HbA1c level . . . on a case-by-case basis, with particular consideration for people who are older or frail, for adults with type 2 diabetes: Y who are unlikely to achieve longer-term riskreduction benefits, for example, people with a reduced life expectancy Y for whom tight blood glucose control poses a high risk of the consequences of hypoglycaemia, for example, people who are at risk of falling, people who have impaired awareness of hypoglycaemia, and people who drive or operate machinery as part of their job • for whom intensive management would not be appropriate, for example, people with significant comorbidities. (7)
Comments
The NICE guideline is based on a clear description of the benefits and harms of tight glycemic control. It encourages patients to be involved in decisions about their HbA 1c target. Target levels range from 6.5% when only diet and exercise are used to manage diabetes, 7% when patients are treated with monotherapy associated with hypoglycemia, and 7.5% when they are treated with combination therapy. The guideline stresses an individualized approach in patients with multiple chronic conditions or limited life expectancy, although it does not define limited life expectancy.
SIGN
Recommendations
An HbA1c target of 7.0% (53 mmol/mol) among people with type 2 diabetes is reasonable to reduce risk of microvascular disease and macrovascular disease. A target of 6.5% (48 mmol/mol) may be appropriate at diagnosis. Targets should be set for individuals in order to balance benefits with harms, in particular hypoglycemia and weight gain (Grade A). (11)
Comments
According to the SIGN grading scheme, grade A corresponds to at least 1 meta-analysis, systematic review, or randomized controlled trial rated as high quality and directly applicable to the target population or a body of evidence consisting principally of studies rated well with low risk of bias, directly applicable to the target population, and showing overall consistency of results (11) .
The SIGN guideline is based on a clear description of the benefits and harms of tight glycemic control. It recommends an HbA 1c target less than 7%. It also recommends individualized targets with no clarity on specific target levels when individualized.
VA/DoD
Recommendations
We recommend setting an HbA1c target range based on absolute risk reduction of significant microvascular complications, life expectancy, patient preferences and social determinants of health. [ 
Comments
The VA/DoD guideline is based on a description of the benefits and harms of glycemic control. It emphasizes the importance of shared decision making in setting HbA 1c goals and recommends target ranges based on comorbid conditions, life expectancy, and other factors rather than setting a fixed target HbA 1c level. It emphasizes that the lower targets of 6.0% to 7.0% and 7.0% to 8.5% should be attained if they can be reached safely. 
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